Kornimate/medical-research-clean huggingface dataset:
quality of life and liver metastases

Conditions: Colorectal Liver Metastases; Quality of Life

Summary: an increasing aggressiveness in the surgical approach of colorectal liver metastases is observed. this seems only justified when, besides prolongation of survival, also the health status of patients is considered. the aim of this prospective study is to investigate the impact of surgery on health-related quality of life in this specific patient population operated for colorectal liver metastases.furthermore, as the indications for hepatic resection are broadened and patients with more extensive liver disease are operated on, the chance of non operable disease at laparotomy will increase. the effects of such an event on hrqol are also studied.

in a prospective study several patients groups were identified. patients undergoing liver resection and/or local ablative therapy. patients with non operable disease at (explorative) laparotomy and outpatients with non operable disease as shown during work up for liver resection. several validated instruments on hrqol were ompleted preoperatively (baseline), a half month after operation and then every three months.

Eligibility criteria:
inclusion criteria: colorectal liver metastases (operable and non operable disease) and participation by means of filling in quality of life instruments exclusion criteria: drop out and therefore loss of quality of life instruments

Keywords: colorectal liver metastases health-related quality of life surgery
study to measure filgotinib in the blood of children and teenagers with arthritis taking filgotinib (scalesia)

Conditions: Juvenile Idiopathic Arthritis

Summary: a study to evaluate the pharmacokinetics, safety, and tolerability in paediatric population for treating juvenile idiopathic arthritis (jia).


Eligibility criteria:
key inclusion criteria: * participant with a body mass index (bmi) within the 5th to 95th percentiles for the age and gender (based on world health organization bmi charts). participant must have a minimum weight of 15 kg. * participant must meet the international league of associations for rheumatology classification for 1 of the following categories and have, according to the investigator's judgment, moderately to severely active disease that is not adequately controlled with his/her current therapy. * rheumatoid factor (rf)-positive polyarthritis * rf-negative polyarthritis * oligoarthritis * psoriatic arthritis * enthesis-related arthritis (era) note: historical human leukocyte antigen b-27 (hla-b27) results are considered appropriate for era diagnosis during screening. * systemic jia with active arthritis without active systemic features, or with active systemic features that are stable in the prior 6 months of time of enrollment * participant with intolerance or a history of inadequate response to at least one of the following medications for the treatment of jia, administered for at least 12 weeks, based on current treatment guidelines: conventional synthetic disease-modifying antirheumatic drugs and biological disease-modifying antirheumatic drugs (including methotrexate) and non-steroidal anti-inflammatory drugs for era and psoriatic arthritis. * female participants of childbearing potential (i.e. who have passed menarche) must have a negative highly sensitive urine pregnancy test. key exclusion criteria: * participant with persistent oligoarthritis. * participant with undifferentiated arthritis. * participant with any other any other rheumatic, inflammatory, or immunologic disease (e.g. inflammatory bowel disease, hypogammaglobulinemia, systemic lupus erythematosus, or uncontrolled uveitis). * active infection that is clinically significant, as per judgment of the investigator. * participant with a history of complicated herpes zoster infection (with multi-dermatomal, disseminated, ophthalmic, or central nervous system involvement). * currently on any therapy for chronic infection (such as pneumocystis, cytomegalovirus, herpes simplex, or atypical mycobacteria). note: other protocol defined inclusion/ exclusion criteria may apply.
mesenchymal stem cells (mscs) in inflammation-resolution programs of coronavirus disease 2019 (covid-19) induced acute respiratory distress syndrome (ards)

Conditions: ARDS; COVID-19

Summary: to evaluate the safety, toxicity and immunological effects of infusion of allogeneic bone marrow-derived human mesenchymal stem (stromal) cells (mscs) and whether this therapy has an influence on the resolution processes in ards patients infected with severe acute respiratory syndrome coronavirus 2 (sars-cov-2).


Eligibility criteria:
inclusion criteria: * covid-19-positive subject * horowitz index ≤ 200 * bilateral opacities on frontal chest radiograph, and * requirement for positive pressure ventilation via an endotracheal tube or non-invasive ventilation * no clinical signs of left atrial hypertension detected via echocardiography, or if measured, a pulmonary arterial wedge pressure (paop) less than or equal to 18 mmhg. * subject's age ≥ 18 years exclusion criteria: * covid-19-negative subject * subject's age \< 18 years * more than 7 days since initiation of mechanical ventilation * patient, surrogate or physician not committed to full intensive care support. * positive pregnancy test at the time of screening. * patients dependent on the sponsor, investigator and their employees, as well as persons dependent on the manufacturer of the investigational drug
effect of percutaneous botulinum toxin a injection on natural course of upper lid retraction in thyroid eye disease

Conditions: Eye Diseases

Summary: in active phase of thyroid eye disease some patients have obvious upper lid retraction , and sometimes exposure keratopathy .to date there is not any standard treatment for this situation . we are going to compare the natural course of the upper lid retraction with injection of botulinum toxin a injection to upper lid percutaneously.


Eligibility criteria:
inclusion criteria: * all the patients wiht oper lid retraction in active phase of thyroid ophthalmopathy exclusion criteria: * patients in non active phase

Keywords: botulinum toxin thyroid eye disease lid retraction
predicting complications of hepatolithiasis after hepatectomy

Conditions: Liver Diseases; Complication

Summary: postoperative complications seriously affect the recovery of patients undergoing hepatectomy. identifying risk factors and develop predictive models of complications for patients with hepatolithiasis undergoing hepatectomy is important for clinical practice.

along with the change of lifestyle and dietary habits, many people are diagnosed with hepatolithiasis that is especially prevalent in asia. liver resection remains the favorable curative therapy for hepatolithiasis with a relatively low recurrence rate. although there have been great improvements in surgical techniques and perioperative management, postoperative complications remain commonplace and seriously threat the recovery of patients undergoing hepatectomy. therefore, it is important to identify risk factors of complications to improve the overall prognosis of patients. we want to collect the clinical information of patients with hepatolithiasis undergoing hepatectomy, including demographic data , laboratory index, histological features and postoperative complications. patients are followed up at a interval of 3 month after treatment, and the survival data and recurrence rate are recorded. then the relationship between clinical data and short-term outcomes after surgery are explored. then models based on clinical features are developed to predict short-term outcomes after hepatectomy.

Eligibility criteria:
inclusion criteria: * pathologically diagnosed hepatolithiasis * without malignancies * receiving liver resection * eastern cooperative oncology group performance status (ecog-ps) 0-2 * child-pugh score of ≤7 * complete clinical and follow-up information * age between 18-80 years old exclusion criteria: * with malignancies * receiving other treatments * eastern cooperative oncology group performance status (ecog-ps) \>2 * child-pugh score of \>7 * incomplete clinical data * lost to follow up * age \ 80 years old

Keywords: liver resection complication risk factor machine learning hepatolithiasis
whole brain radiotherapy with or without temozolomide at daily fixed-dose for brain metastases treatment

Conditions: Brain Neoplasms

Summary: rationale * fractionated radiotherapy uses high-energy photons to kill, or damage tumor cells. high daily dose temozolomide combined with fractionated radiotherapy may make tumor cells more sensible to treatment. purpose * this randomized phase ii trial, assess in patients with brain metastases from solid tumors, whether the whole brain radiotherapy (wbrt) plus temozolomide is able to improve the results obtained with wbrt.

primary outcome measures * objective response rates secondary outcome measures * survival free of brain metastases progression * overall survival * systemic side effects objectives primary * compare objective response rates in both arms of treatment secondary * compare survival free of progression in both arms of treatment * compare overall survival in both arms of treatment * compare side effects

Eligibility criteria:
inclusion criteria: * karnofsky performance status (kps) ≥ 50 * life expectancy ≥ 12 weeks * histologically confirmed non lymphomatous solid tumors at primary site * brain metastases diagnosed with cranial mri/ct. * extracranial metastases or primary tumor uncontrolled are allowed * hemoglobin ≥ 10 g/dl * absolute neutrophil count of \> 1500/mm3 * platelet count of ≥ 100,000/mm3 * blood urea nitrogen (bun) ≤ 25 mg/dl, * serum creatinin ≤ 1.5 mg/dl * serum bilirubins ≤ 1.5 mg/dl, * alanine aminotransferase (alt) and aspartate aminotransferase (ast) ≤ twice the upper normal limit exclusion criteria * pregnant or breast feeding woman * history of allergic reaction to iodinated contrast media * inability to swallow * systemic chemotherapy in previous 3 weeks * oral chemotherapy in previous 2 weeks * prior surgery, chemotherapy, or radiotherapy for a brain neoplasm * meningeal carcinomatosis

Keywords: brain metastases temozolomide whole-brain radiotherapy phase ii trial
a study of the efficacy and safety of nebivolol added to existing antihypertensive treatment in patients with hypertension

Conditions: Hypertension

Summary: the purpose of this study was to contrast the efficacy and safety of 3 dose levels of nebivolol vs. placebo, when added to a patient's existing antihypertensive medication(s) for 3 months, in patients with mild to moderate hypertension

following a washout of any previous beta-blocker medication, if applicable, supine, sitting, and standing cuff blood pressure and pulse rate, 24-hour ambulatory blood pressure monitoring (abpm), ecg, laboratory assessments and genomics testing were performed before randomization. patients were randomized to receive placebo or nebivolol once daily in the morning together with their curently prescribed antihypertensive therapy. patients had four scheduled clinical visits during the study, following the screening visit.

Eligibility criteria:
inclusion criteria: * average sitting diastolic blood pressure (dbp) greater then or equal to 90 mmhg and less then or equal to 109 mmhg at screening and baseline, in patients on background antihypertensive therapy taking at least one and no more than two of either ace inhibitor, arb, or diuretic. exclusion criteria: * recent myocardial infarction or stroke * contraindications to beta-blocker therapy

Keywords: nebivolol beta-blocker hypertension
effectiveness of cohesive bandage on axillary web syndrome after

Conditions: Axillary Web Syndrome

Summary: objective: to determine the effectiveness of cohesive bandage on the axillary web syndrome in improving pain, reducing swelling and increasing mobility and functionality of the shoulder. design: randomized single-blinded controlled trial. follow-up: five physical therapy assessments: pre-intervention; post-intervention, 3 and 6 months post-intervention post-intervention. participants: 90 consecutive women diagnosed with axillary web syndrome after undergoing unilateral breast cancer surgery with alnd or slnd at the prıíncipe de asturias hospital in alcalà de henares, madrid (spain). randomization: women will be randomly assigned to two groups by epidata 3.1 software. interventions: control group: physical therapy composed of manual lymph-drainage technique in axilla, and proximal ipsilateral arm, specific thumb manual lymph-drainage on the taut cords to make them gradually more flexible, in conjunction with progressive active arm therapeutic exercises; intervention group: progressive active arm therapeutic exercises with cohesive bandage.


Eligibility criteria:
inclusion criteria: * unilateral breast cancer; * breast surgery with lymphadenectomy and / or sentinel lymph node biopsy; * axillary web syndrome in upper limb of the operated side; * consent to participate in the study; * no contraindications. exclusion criteria: * cognitive impairment; * visual impairment for reading; * lymphedema; * bilateral breast cancer; * systemic disease (metastases), * infection; * locoregional recurrence.

Keywords: cohesive bandage physical therapy pain
study of the safety and immune response of two serogroup b meningococcal vaccines administered to healthy adolescents

Conditions: Meningococcal Disease

Summary: the purpose of this study is to evaluate the safety and immunogenicity of two serogroup b meningococcal vaccines in comparison to placebo administered to healthy adolescents ages 11 to 18 years.


Eligibility criteria:
inclusion criteria: * healthy adolescents between and including 11-18 years of age, who provide written informed consent. exclusion criteria: * previous or suspected disease caused by n. meningitidis; or previous immunization with a serogroup b meningococcal vaccine; any acute, chronic or progressive disease.

Keywords: meningococcal disease; meningococcal meningitis; vaccine
citicoline and omega-3 fatty acid effects in veterans with traumatic brain injury (tbi)

Conditions: Traumatic Brain Injury; Substance Abuse; Substance Dependence

Summary: this is a placebo-controlled study intended to examine the effects of the neutraceutical citicholine, together with omega-3 fatty acids, on a range of measures in individuals with concussive head injury, often referred to as traumatic brain injury, or tbi. the study will consist of three visits, during which participants will complete brain scans, a thorough testing battery and a clinical interview to assess mood and other diagnostic information relevant to the study.


Eligibility criteria:
inclusion criteria: * veteran status * age 18 to 55 * history of tbi * dsm-iv-tr diagnosis of abuse or dependence disorder for either alcohol or drugs of abuse * multiple concussive head injuries that meet the following criteria for tbi: 1) normal structural imaging, 2) loss of consciousness (loc) between 0-30 minutes, 3) alteration of consciousness or mental status for a moment up to 2 hours or 4) post-traumatic amnesia of 0-1 day * stable on current psychotropic medication regimen for ≥ 3 months exclusion criteria: * non veteran * significant medical or neurological illness with the exception of tbi, which might affect cognitive function * significant medical illness which has the potential to be exacerbated by ingestion of citicoline/omega-3 fatty acids, including diabetes, congestive heart disorder, hyperlipidemia and severe coronary artery disease * age other than 18 to 55 years old * history of ect treatment * estimated iq \< 70 * past or present history of bipolar disorder, schizophrenia, delusional disorder or any other psychotic disorder * currently taking a prescribed blood thinner (i.e., coumadin) * claustrophobia * metal implanted within the body * pregnancy or lactation * left-handedness * poor vision, as subjects must have normal or corrected-to-normal vision for viewing of cognitive challenge paradigms during fmri protocols * non-native english speakers (for neurocognitive tasks)

Keywords: veterans traumatic brain injury tbi substance abuse substance dependence veterans with traumatic brain injury (tbi) veterans with substance abuse or dependence
the efficacy of sequential therapy as second line therapy for refractory helicobacter pylori infection - a pilot study

Conditions: H. Pylori Infection

Summary: helicobacter pylori infection has been shown to be associated with the development of gastric cancer and peptic ulcer diseases. eradication of h. pylori infection could reduce the occurence or recurrence of these diseases. however, it was estimated that 15-20% of patients would fail from first line standard eradication therapy and need second line rescue therapy. about 15-30% of patient would fail from second line therapy and need to be rescued with third line therapy. the commonly used salvage regimens include: 1. bismuth based quadruple therapy (combined with ranitidine or proton-pump inhibitor (ppi) plus two antibiotics) 2. levofloxacin or moxifloxacin or rifabutin based triple therapy. however, bismuth is not available in many countries and the administration method is complex. its usage is limited by the high pill number and low compliance rate. in recent years, the concept of sequential therapy has been advocated in the treatment of h. pylori infection. the regimen includes a ppi plus amoxicillin for five days, followed by a ppi plus clarithromycin and metronidazole for another five days. the eradication rate in the first line treatment of sequential therapy had been reported to be as high as 90%. more importantly, it has been demonstrated that the eradication rate among patients with clarithromycin-resistant strains could be as high as 89%. aims: therefore, the investigators aim to assess the efficacy of levofloxacin-based sequential therapy as second line therapy for those who fail from one standard eradication therapy.


Eligibility criteria:
inclusion criteria: * patients are aged greater than 20 years who have persistent h. pylori infection after one treatment and are willing to receive second line rescue regimens, respectively, are considered eligible for enrollment. exclusion criteria: * children and teenagers aged less than 20 years, * history of gastrectomy, * gastric malignancy, including adenocarcinoma and lymphoma, * previous allergic reaction to antibiotics (amoxicillin, clarithromycin, levofloxacin) and prompt pump inhibitors (esomeprazole), * contraindication to treatment drugs, * pregnant or lactating women, or * severe concurrent disease.

Keywords: helicobacter pylori sequential therapy levofloxacin clarithromycin rescue salvage treatment failure for those who fail from one standard eradication therapy for h. pylori infection
motor intervention for children with developmental coordination disorder

Conditions: Developmental Coordination Disorder

Summary: this study focuses on the effects of physical activity in schools on the cognitive function and physical fitness of children with and without developmental coordination disorder (dcd). methods: 58 children with dcd participated in an 8-week exercise program. children's standing broad jump (sbj), 50m dash, 50m\*8 shuttle run, mental rotation and executive functions were assessed before and after training. a mixed-design analysis of variance (anova) was conducted separately for each performance variable.

potential children were identified from elementary schools in three districts of shanghai. the study protocol was approved by the ethics committee of shanghai uni-versity of medicine and health sciences. in order to select the research sample, recruitment letters were sent to the parents of all children; these letters detailed the purpose, significance and research process of the study, and a consent form was attached. if parents were willing to participate in the study, they were asked to sign the consent form and scan the qr code to fill in the questionnaire, including dcdq, the attention deficit/hyperactivity disorder (adhd) rating scale-vi and other personal information. all questionnaire contents were only accessible to research team members, and the researcher's name and telephone number were provided in case parents had questions. a total of 2,761 children and their parents volunteered to participate in this study. children were screed using the developmental coordination disorder questionnaire (dcdq) . teachers selected those children with probable dcd but without any intellectual or cognitive impairment. these children were then tested using the movement assessment battery for children, 2nd edition. finally, 116 pdcd children were randomly divided into a training group (tg, mean age 10.67 ± 1.25 years, 50 boys and 8 girls) and a control group (cg, mean age 10.27 ± 1.04 years, 48 boys and 10 girls) and gender matched typically developing (td, mean age 10.35 ± 1.87 years; 48 boys and 12 girls) controls were included in the study. tg and td will receive an additional 8 weeks of physical training intervention, while cg will not participate in the physical training intervention.

Eligibility criteria:
inclusion criteria: * dcdq scores as follows: (8-9 years: \< 56 points; 10-12 years: \< 58 points) * one subitem of the mabc-2 rank below 15% * age 9 to 11 years old (elementary school age) exclusion criteria: * children with other mental illness who are unable to exercise * iq \>90 * adhd
enteral administration of docosahexaenoic acid to prevent retinopathy of prematurity

Conditions: Retinopathy of Prematurity

Summary: the purpose of this study is to evaluate whether docosahexaenoic acid given by enteral feeding prevent retinopathy of prematurity and/or diminish its severity in preterm infants.

preterm neonates who start receiving enteral feeding will receive the intervention with docosahexaenoic acid (dha) since the first day and throughout 14 days, one dose per day. the opthalmic evaluation will be done after 4-5 weeks after birth and followed until 42-45 corrected gestational age.

Eligibility criteria:
inclusion criteria: * birth weight \< 1500 g * plan to feed by enteral way at a short term * written informed consent, signed by both parents. exclusion criteria: * congenital malformations that avoid enteral feeding * immunosuppressor diseases * need for major surgery * persistent bleeding at any level * mother taking n-3 supplements and planning to breastfed * parents who decline the authorization for participating in the study * early discharge to other hospital outside the metropolitan area

Keywords: dha retinopathy of prematurity
obesity, insulin resistance, and pasc: persistent sars-cov-2

Conditions: Long COVID; Insulin Resistance; Insulin Sensitivity

Summary: the investigators are studying the pathophysiologic links between obesity, insulin resistance (ir), adipose tissue infection, and post-acute sequelae of covid-19 (pasc). this study looks at whether adipose (fat) tissue contributes to pasc by driving chronic inflammation or by serving as a reservoir for sars-cov-2 persistence. the results will not only determine whether obesity and ir are risk factors for pasc, but will also define fundamental biology that sets the stage for the investigation of novel or existing therapies that target the causal pathways identified.


Eligibility criteria:
inclusion criteria: * ages 18 to 80 * bmi ≥ 25 kg/m2 * not currently pregnant exclusion criteria: arm 2 (adipose tissue biopsy) exclusions include * pregnancy * prior liposuction * recent change in weight (\> 2 kg in one month) * bleeding disorders * anticoagulant use arm 3 (healthy controls only) exclusions include patients with * major organ disease * diabetes * history of liposuction * bariatric surgery * eating disorders * psychiatric disorders * pregnancy or lactation * recent change in weight (over the past 12 weeks), * use of weight loss medication or oral steroids * hematocrit \< 33% * fasting glucose \>= 126 mg/dl * blood pressure \>160/100 mmhg